Debanjana Chatterjee, an analyst from JonesTrading, maintained the Buy rating on Spyre Therapeutics. The associated price target is $64.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Debanjana Chatterjee has given his Buy rating due to a combination of factors tied to Spyre Therapeutics’ lead asset and its positioning in inflammatory diseases. He views TL1A as an innovative and mechanistically well‑supported target in rheumatic conditions, particularly in rheumatoid arthritis, where the biological rationale appears especially compelling. The ongoing SKYWAY Phase 2 basket trial with SPY072 across rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis is seen as a key value driver, as successful proof‑of‑concept data expected in 2026 could establish a new therapeutic pathway within inflammatory arthritis. The company’s strong cash position is also noted as providing sufficient runway to execute on this development plan.
Debanjana Chatterjee also incorporates expert validation and market dynamics into his positive stance. By engaging a prominent rheumatology KOL, he seeks to deepen conviction around the scientific underpinnings, competitive landscape, clinically meaningful efficacy thresholds, and real‑world adoption potential of TL1A inhibition. If SPY072 can demonstrate robust clinical signals and meet or exceed current efficacy benchmarks in RA, PsA, and axSpA, he believes it could be integrated favorably into treatment algorithms and capture meaningful share in a large, still‑underserved market. Together, these scientific, clinical, and financial considerations underpin his Buy rating and $64 price target on Spyre Therapeutics.
Chatterjee covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals, Intellia Therapeutics, and Opus Genetics. According to TipRanks, Chatterjee has an average return of 35.2% and a 71.30% success rate on recommended stocks.
In another report released on December 18, Mizuho Securities also initiated coverage with a Buy rating on the stock with a $53.00 price target.